Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;13(2):905-911.
doi: 10.3892/ol.2016.5494. Epub 2016 Dec 14.

Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy

Affiliations

Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy

Akio Higuchi et al. Oncol Lett. 2017 Feb.

Abstract

Overall survival remains unsatisfactory in stage II/III gastric cancer, even after curative surgery and adjuvant chemotherapy. Platelet-derived growth factor receptor-β (PDGFR-β) is associated with the proliferation of cancer cells. The present study therefore investigated the association of PDGFR-β gene expression with patient outcome in 134 stage II/III gastric cancer patients who received adjuvant chemotherapy with S-1. Relative PDGFR-β gene expression was measured in surgical cancer tissue and adjacent normal mucosa specimens by reverse transcription-quantitative polymerase chain reaction. The PDGFR-β gene expression levels were found to be significantly higher in the cancer tissues compared with the adjacent normal mucosa. A high level of PDGFR-β gene expression was associated with a significantly poorer 5-year overall survival rate compared with a low level of PDGFR-β expression. Upon multivariate analysis, PDGFR-β gene expression was found to be an independent predictor of survival. Overall, the study indicates that PDGFR-β overexpression in gastric cancer tissues is a useful independent predictor of outcome in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S-1.

Keywords: PDGFR-β; adjuvant chemotherapy with S-1; prognostic factor; stage II/III gastric cancer; tyrosine kinase receptor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Reverse-transcription polymerase chain reaction. Expression of platelet-derived growth factor receptor-β (PDGFR-β) mRNA was significantly higher in the cancer tissue (T) than in the paired normal adjacent mucosa (N). m, (molecular) marker; p, positive control; n, negative control.
Figure 2.
Figure 2.
Comparison of platelet-derived growth factor receptor-β (PDGFR-β) mRNA expression levels between gastric cancer tissue and adjacent normal mucosa. Box boundaries represent the 25th and 75th percentiles of the observed values, capped bars represent the 10th and 90th percentiles, and the solid line represents the median. P-values were calculated by the Wilcoxon signed-rank test. Expression levels of the PDGFR-β gene were higher in the cancer tissues than in the adjacent normal mucosa (P=0.009).
Figure 3.
Figure 3.
Immunohistochemical analysis of platelet-derived growth factor receptor-β (PDGFR-β) expression. Expression of PDGFR-β protein was evaluated by immunohistochemical analysis of resected specimens of gastric cancer. Positive staining for PDGFR-β was observed in the tumor stromal cells of gastric cancer tissue in (A) differentiated and (B) undifferentiated types of gastric cancer.
Figure 4.
Figure 4.
Association between platelet-derived growth factor receptor-β (PDGFR-β) mRNA expression and post-operative survival. Expression levels of the PDGFR-β gene were categorized as low or high according to the median value. The post-operative survival rate was analyzed by the Kaplan-Meier method, and differences in survival rates were assessed by the log-rank test. Overall survival was significantly poorer in patients with high expression levels of the PDGFR-β gene than in those with low expression levels (P=0.045).

Similar articles

Cited by

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820. doi: 10.1056/NEJMoa072252. - DOI - PubMed
    1. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767–2773. doi: 10.1200/JCO.2004.10.184. - DOI - PubMed
    1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393. doi: 10.1200/JCO.2011.36.5908. - DOI - PubMed
    1. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, Chayama K. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci. 2010;101:1984–1989. doi: 10.1111/j.1349-7006.2010.01639.x. - DOI - PMC - PubMed